Isis Pharmaceuticals Inc (ISIS.OQ)

ISIS.OQ on NASDAQ Stock Exchange Global Select Market

29.32USD
10:57am EDT
Price Change (% chg)

$0.47 (+1.63%)
Prev Close
$28.85
Open
$29.13
Day's High
$30.00
Day's Low
$28.90
Volume
105,693
Avg. Vol
508,220
52-wk High
$34.30
52-wk Low
$7.55

ISIS.OQ

Chart for ISIS.OQ

About

Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. The Company's principal activity is to develop and market RNA(RiboNucleicAcid)-based novel drugs to treat important diseases such as cardiovascular diseases, diabetes and asthma

Overall

Beta: 1.11
Market Cap (Mil.): $3,222.41
Shares Outstanding (Mil.): 111.70
Dividend: --
Yield (%): --

Financials

  ISIS.OQ Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -0.43 -- --
ROI: -9.68 -2.58 18.76
ROE: -24.52 -2.66 19.59
Search Stocks

Isis eyes nationwide mobile payments launch this year

NEW YORK - Isis, a venture of three of the top U.S. mobile providers, said on Tuesday it would expand its much-delayed mobile payments service nationwide later in 2013 after it tested the concept with consumers in two markets.

30 Jul 2013

Isis Pharma drug reduces blood fat by 64 pct in mid-stage study

- Isis Pharmaceuticals Inc said its experimental drug reduced the level of triglycerides, a type of fat in the blood that increases the risk of heart diseases, by up to 64 percent in a mid-stage trial.

22 Jul 2013

Isis Pharma drug reduces blood fat by 64 pct in mid-stage study

July 22 - Isis Pharmaceuticals Inc said its experimental drug reduced the level of triglycerides, a type of fat in the blood that increases the risk of heart diseases, by up to 64 percent in a mid-stage trial.

22 Jul 2013

Isis shares jump after experimental drug cuts blood fat

- Shares of Isis Pharmaceuticals Inc rose as much as 24 percent after the drugmaker said its experimental drug reduced triglycerides, a type of fat, in blood and increased the level of "good" cholesterol.

24 Jun 2013

Roche to use Isis's technology to develop brain disorder drug

- Isis Pharmaceuticals Inc said it will form an alliance with Swiss drugmaker Roche Holding AG to develop treatments for Huntington's disease, a genetic brain disorder, based on the U.S. company's technology.

08 Apr 2013

Roche to use Isis's technology to develop brain disorder drug

April 8 - Isis Pharmaceuticals Inc said it will form an alliance with Swiss drugmaker Roche Holding AG to develop treatments for Huntington's disease, a genetic brain disorder, based on the U.S. company's technology.

08 Apr 2013

Competitors

  Price Change
Pfizer Inc. (PFE.N) $29.19 -0.04
Novartis AG (NOVN.VX) CHF66.60 +0.35
Merck & Co., Inc. (MRK.N) $48.10 -0.07
Roche Holding Ltd. (ROG.VX) CHF228.00 -3.50
GlaxoSmithKline plc (GSK.L) 1,706.50p +22.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$58.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks